Moreover, the lack of assessing combinations of MAPKCIs for aggregate targeting of the MAPKC should also be addressed in NSCLC, as recent studies have already revealed promising results for p38 MAPK and JNK inhibitors in other cancers [128,178]. This evidence concerns the gene MAPK8 and cancer.